- Home
- IMNN vs CNVS Comparison
IMNN vs CNVS Comparison
Compare IMNN & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- CNVS
- Stock Information
- Founded
- IMNN 1982
- CNVS 2000
- Country
- IMNN United States
- CNVS United States
- Employees
- IMNN N/A
- CNVS N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- CNVS Consumer Electronics/Video Chains
- Sector
- IMNN Health Care
- CNVS Consumer Discretionary
- Exchange
- IMNN Nasdaq
- CNVS Nasdaq
- Market Cap
- IMNN 12.9M
- CNVS 46.9M
- IPO Year
- IMNN 1985
- CNVS 2003
- Fundamental
- Price
- IMNN $3.77
- CNVS $2.41
- Analyst Decision
- IMNN Buy
- CNVS Buy
- Analyst Count
- IMNN 2
- CNVS 2
- Target Price
- IMNN $182.61
- CNVS $9.50
- AVG Volume (30 Days)
- IMNN 56.4K
- CNVS 174.6K
- Earning Date
- IMNN 11-13-2025
- CNVS 11-14-2025
- Dividend Yield
- IMNN N/A
- CNVS N/A
- EPS Growth
- IMNN N/A
- CNVS N/A
- EPS
- IMNN N/A
- CNVS N/A
- Revenue
- IMNN N/A
- CNVS $79,791,000.00
- Revenue This Year
- IMNN N/A
- CNVS N/A
- Revenue Next Year
- IMNN N/A
- CNVS $36.66
- P/E Ratio
- IMNN N/A
- CNVS N/A
- Revenue Growth
- IMNN N/A
- CNVS 77.29
- 52 Week Low
- IMNN $3.56
- CNVS $2.24
- 52 Week High
- IMNN $41.22
- CNVS $7.39
- Technical
- Relative Strength Index (RSI)
- IMNN 35.44
- CNVS 32.56
- Support Level
- IMNN $3.56
- CNVS $2.36
- Resistance Level
- IMNN $4.38
- CNVS $2.76
- Average True Range (ATR)
- IMNN 0.30
- CNVS 0.23
- MACD
- IMNN 0.00
- CNVS 0.01
- Stochastic Oscillator
- IMNN 21.95
- CNVS 13.16
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.